The Effects of Piroxicam and Deracoxib on Canine Mammary Tumour Cell Line

Table 2

Effects of piroxicam and deracoxib combination on cell cycle phase distribution of CMT-U27 cells. Data are expressed as mean values ± standard error of means shown with *𝑃<0.05 versus control group.

Drug concentrations	% G0/G1	% S	% G2/M
Control	63.8 ± 2.11	22.48 ± 1.52	13.72 ± 1.50
Piroxicam + deracoxib (50 + 50 μM)	67.4 ± 3.04	19.97 ± 1.63	12.63 ± 1.26
Piroxicam + deracoxib (100 + 100 μM)	64.53 ± 2.51	22.27 ± 1.22	13.2 ± 1.10
Piroxicam + deracoxib (250 + 250 μM)	69.58 ± 3.50	17.75 ± 1.45	12.67 ± 0.76
Piroxicam + deracoxib (500 + 500 μM)	72.2 ± 2.17	19.95 ± 1.12	7.85 ± 1.51
Piroxicam + deracoxib (1000 + 1000 μM)	89.95 ± 3.35*	8.27 ± 1.81*	1.78 ± 0.68*